TARRYTOWN, N.Y., May 29, 2020 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has
completed the secondary offering of 13,014,646 shares of its common
stock held by Sanofi, which includes the exercise in full of the
underwriters' option to purchase additional shares from Sanofi, at
a public offering price of $515.00
per share. The Company also announced the completion of its
repurchase of 9,806,805 shares directly from Sanofi at a price of
$509.85 per share (representing the
price paid by the underwriters in the offering), for an aggregate
purchase amount of $5 billion.
Pursuant to the offering and repurchase, Sanofi has disposed of all
of its shares of common stock in Regeneron, other than 400,000
shares that it is retaining.
Regeneron did not receive any of the proceeds from the sale of
shares of its common stock by Sanofi. The public offering occurred
simultaneously in the United
States and internationally through underwriters led by BofA
Securities and Goldman Sachs & Co. LLC, together with Barclays,
BNP Paribas, Citigroup, J.P. Morgan, Morgan Stanley as joint
book-running managers.
Regeneron has filed a registration statement (including a
prospectus) with the SEC for the offering. Before you invest, you
should read the prospectus in that registration statement and other
documents Regeneron has filed and will file with the SEC, including
the final prospectus supplement dated May
26, 2020, for more complete information about Regeneron and
this offering. You may get these documents for free by visiting
EDGAR on the SEC website at www.sec.gov. Alternatively, any
underwriter or any dealer participating in the offering will
arrange to send you the prospectus and the prospectus supplement,
if you request them by contacting BofA Securities, NC1-004-03-43,
200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department or by email at
dg.prospectus_requests@bofa.com; or Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone:
1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com.
This announcement shall not constitute an offer to sell or
the solicitation of any offer to buy, nor shall there be any sale
of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for over 30 years by physician-scientists,
Regeneron's unique ability to repeatedly and consistently translate
science into medicine has led to seven FDA-approved treatments and
numerous product candidates in development, all of which were
homegrown in Regeneron's laboratories. Regeneron's medicines and
pipeline are designed to help patients with eye diseases, allergic
and inflammatory diseases, cancer, cardiovascular and metabolic
diseases, pain, infectious diseases, and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through its proprietary
VelociSuite® technologies, such as
VelocImmune®, which uses unique
genetically-humanized mice to produce optimized fully-human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics
Center®, which is conducting one of the largest genetics
sequencing efforts in the world.
Forward-Looking Statements
This press release may include forward-looking statements
that involve risks and uncertainties relating to future events or
our future operations, performance or financial condition, and
actual events or results may differ materially from these
forward-looking statements. Words such as "anticipate," "expect,"
"intend," "plan," "believe," "seek," "estimate," variations of such
words, and similar expressions are intended to identify such
forward-looking statements, although not all forward-looking
statements contain these identifying words. Risks that may cause
these forward-looking statements to be inaccurate include, among
others the impact of general economic, industry, or political
conditions in the United States or
internationally, including as a result of, among other risks and
uncertainties, the impact of SARS-CoV-2 (the virus that has caused
the COVID-19 pandemic) on Regeneron's business and its employees,
collaborators, suppliers, and other third parties on which
Regeneron relies, Regeneron's and its collaborators' ability to
continue to conduct research and clinical programs, Regeneron's
ability to manage its supply chain, net product sales of products
marketed by Regeneron and/or its collaborators (collectively,
"Regeneron's Products"), and the global economy; the impact of the
transactions discussed in this press release on Regeneron's
business and financial condition; the nature, timing, and possible
success and therapeutic applications of Regeneron's Products and
Regeneron's product candidates and research and clinical programs
now underway or planned, including without limitation
EYLEA® (aflibercept) Injection, Dupixent®
(dupilumab), Libtayo® (cemiplimab), Praluent®
(alirocumab), Kevzara® (sarilumab), fasinumab,
evinacumab, REGN-EB3, garetosmab, pozelimab, Regeneron's oncology
programs (including its costimulatory bispecific portfolio),
Regeneron's COVID-19 antibody program and other earlier-stage
programs, and the use of human genetics in Regeneron's research
programs; the likelihood and timing of achieving any of our
anticipated development milestones; unforeseen safety issues
resulting from the administration of Regeneron's Products and
product candidates in patients, including serious complications or
side effects in connection with the use of Regeneron's Products and
product candidates in clinical trials; the likelihood and timing of
possible regulatory approval and commercial launch of Regeneron's
late-stage product candidates and new indications for Regeneron's
Products, including without limitation EYLEA, Dupixent, Libtayo,
Praluent, Kevzara, fasinumab, evinacumab, garetosmab, pozelimab,
REGN1979, and REGN-EB3; the extent to which the results from the
research and development programs conducted by Regeneron or its
collaborators may be replicated in other studies and lead to
therapeutic applications; ongoing regulatory obligations and
oversight impacting Regeneron's Products (such as EYLEA, Dupixent,
Libtayo, Praluent, and Kevzara), research and clinical programs,
and business, including those relating to patient privacy;
determinations by regulatory and administrative governmental
authorities which may delay or restrict Regeneron's ability to
continue to develop or commercialize Regeneron's Products and
product candidates; competing drugs and product candidates that may
be superior to Regeneron's Products and product candidates;
uncertainty of market acceptance and commercial success of
Regeneron's Products and product candidates and the impact of
studies (whether conducted by Regeneron or others and whether
mandated or voluntary), on the commercial success of Regeneron's
Products and product candidates; the ability of Regeneron to
manufacture and manage supply chains for multiple products and
product candidates; the ability of Regeneron's collaborators,
suppliers, or other third parties (as applicable) to perform
manufacturing, filling, finishing, packaging, labeling,
distribution, and other steps related to Regeneron's Products and
product candidates; coverage and reimbursement determinations by
third-party payors, including Medicare and Medicaid; unanticipated
expenses; the costs of developing, producing, and selling products;
the ability of Regeneron to meet any of its financial projections
or guidance and changes to the assumptions underlying those
projections or guidance; the potential for any license or
collaboration agreement, including Regeneron's agreements with
Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their
respective affiliated companies, as applicable), to be cancelled or
terminated without any further product success; and risks
associated with intellectual property of other parties and pending
or future litigation relating thereto (including without limitation
the patent litigation and other related proceedings relating to
Dupixent and Praluent), other litigation and other proceedings and
government investigations relating to the Company and/or its
operations, the ultimate outcome of any such proceedings and
investigations, and the impact any of the foregoing may have on
Regeneron's business, prospects, operating results, and financial
condition. A more complete description of these and other material
risks can be found in Regeneron's filings with the U.S. Securities
and Exchange Commission, including its Form 10-K for the fiscal
year ended December 31, 2019 and its
Form 10-Q for the quarterly period ended March 31, 2020. Any forward-looking statements
are made based on management's current beliefs and judgment, and
the reader is cautioned not to rely on any forward-looking
statements made by Regeneron. Regeneron does not undertake any
obligation to update publicly any forward-looking statement,
including without limitation any financial projection or guidance,
whether as a result of new information, future events, or
otherwise.
Regeneron
Contacts:
Media
Relations
Hala Mirza
Tel: +1 (914)
847-3422
Hala.Mirza@regeneron.com
|
Investor
Relations
Justin
Holko
Tel: +1 (914)
450-3514
Justin.Holko@regeneron.com
|
View original
content:http://www.prnewswire.com/news-releases/regeneron-completes-secondary-offering-of-common-stock-held-by-sanofi-301067910.html
SOURCE Regeneron Pharmaceuticals, Inc.